Androclus Therapeutics Announces Formation Of Clinical Advisory Board.

SAN DIEGO & MILAN, Italy -- Androclus Therapeutics announced today the formation of a Clinical Advisory Board (CAB) for Neurology, which has been assembled to guide the company in the clinical development of therapeutics for autoimmune diseases such as multiple sclerosis.

Androclus' clinical drug candidate for the treatment of multiple sclerosis, AT-008, is an orally administered immunomodulatory peptide, currently undergoing preclinical testing.

The Clinical Advisory Board, composed of leading experts in the field of Multiple Sclerosis and Immunology, will be instrumental in defining Androclus' clinical development strategy and in designing and implementing upcoming clinical trials of AT-008 for the treatment of multiple sclerosis.

The Androclus Therapeutics Clinical Advisory Board is now composed of:

--David Hafler, M.D. is Professor of Neurology and Director of the Laboratory of Molecular Immunology at the Harvard Medical School. He also is a physician at the Brigham and Women's Hospital. Dr. Hafler is founder and co-chair of Federation of Clinical Immunology Societies and a member of editorial boards of Journal of Neuroimmunology and Journal of Clinical Investigation.

--Robert M. Herndon, M.D. is Professor of Neurology at the University of Mississippi and Editor of the International Journal of MS Care. He is past president of the Consortium of MS Centers and a member of the Medical Advisory Board of the National Multiple Sclerosis Society.

--Antonio Uccelli, M.D. is Assistant Professor at the Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Italy. He is also a faculty member of the Multiple Sclerosis Clinic of the University of Genoa. Dr. Uccelli is a member of the Executive Board of the Italian Society of Neuroimmunology and is the Secretary of the Scientific Committee of the Italian Multiple Sclerosis Society.

"With the expected initiation of clinical trials for our drug candidate for multiple sclerosis AT-008 approaching in 2005, I am very pleased that we have been able to attract individuals with strong reputations and the depth of experience in multiple sclerosis and immunology," said Igor Bilinsky, Ph.D., Androclus' Chief Operating Officer. "We look forward to a long and successful relationship with our new Advisors."

About Androclus Therapeutics

Androclus Therapeutics is a private clinical stage biotechnology company with a mission to discover and develop novel therapeutics and technologies for the treatment of diseases involving the immune system, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Androclus' leading drug candidate, AT-001 (dnaJP1), is an orally administered peptide for the treatment of rheumatoid arthritis, currently in a Phase II clinical trial. A previously completed Phase I/IIa trial of AT-001 demonstrated safety, biological efficacy and provided evidence of clinical efficacy. The approach is based on restoration of regulatory Tcell activity that is impaired in patients with autoimmune diseases. Androclus has partnered AT-001 with a large biotechnology company. Building on the success of AT-001, Androclus is now developing orally administered therapeutic peptides for the treatment of multiple sclerosis and inflammatory bowel disease, currently in the preclinical stage. For more information, visit Androclus' web site at www.androclus.com.